Skip to main content
. 2022 Nov;33(11):1966–1979. doi: 10.1681/ASN.2022040413

Figure 2.

Figure 2.

Mean Hb changes from baseline in nondialysis and dialysis patients. (A) Nondialysis patients. Mean Hb changes from baseline in the main phase 3 randomized clinical trials testing HIF-PHI compared with placebo or darbepoetin alfa. (B) Dialysis patients. Mean Hb changes from baseline in the main phase 3 randomized clinical trials testing HIF-PHI compared with ESA.